Enzo Biochem Inc

Enzo Biochem — Proxy Contest (December 2015)

91 slides from Enzo Biochem's proxy contest presentation, Dec 21, 2015

  1. Slide 1: December Investor Presentation – As Updated on December 21st, 2015

    December 2015 www.enzo.com December Investor Presentation – As Updated on December 21 st , 2015

  2. Slide 2: Disclaimer

    1 DISCLAIMER Except for historical information, the matters discussed herein may be considered "forward - looking" statements within the meaning of Section 27 A of the Securities Act of 1933 , as amended, and Section 21 E of the Securities Exchange Act of 1934 , as amended . Such statements include

  3. Slide 3: Proxy statement participant notice

    2 Enzo Biochem, Inc . (the “Company”) has filed a definitive proxy statement with the U . S . Securities and Exchange Commission (the "SEC") with respect to its 2015 Annual Meeting of Shareholders and intends to file a definitive proxy statement as well . The definitive proxy statement and white pro

  4. Slide 4: Table of Contents

    3 TABLE OF CONTENTS Page Executive Summary 4 Enzo Now 7 The Problems with Lone Star 27 Addressing Lone Star’s December 17 th Presentation to ISS 34 Additional Background on Lone Star 57 Enzo’s Leadership 84

  5. Slide 5: Executive Summary

    December 2015 www.enzo.com Executive Summary 4

  6. Slide 6: Executive Summary - Enzo

    5 EXECUTIVE SUMMARY - ENZO x Executing on a corporate strategy which has positioned the company to thrive in the challenging MDx marketplace x The value of Enzo is beginning to be appreciated by the marketplace: delivering solid returns to shareholders – 3 - year TSR of 71.9%, 6 - month TSR of 86.0%

  7. Slide 7: Executive Summary – Lone Star

    6 EXECUTIVE SUMMARY – LONE STAR  Aggressively reducing its Enzo ownership while simultaneously pursuing a proxy fight (see pages 30 - 31)  Has not presented a single idea , plan, or alternative perspective on how Enzo can increase shareholder returns  Has resorted to personal attacks on Enzo’s di

  8. Slide 8: Enzo Now

    December 2015 www.enzo.com Enzo NOW 7

  9. Slide 9: Enzo Is Positioned to Thrive Now

    8 Enzo Is Positioned to Thrive NOW

  10. Slide 10: Why Enzo Is Positioned to Thrive Now

    9 WHY ENZO IS POSITIONED TO THRIVE NOW  Why NOW?  Molecular diagnostics market place is rapidly growing but economics are poor and will decline further for clinical labs  The advent of open system platforms (<5 years) for labs creates opportunity for a vertically integrated technology development

  11. Slide 11: Enzo's Time Is Now

    10 ENZO’S TIME IS NOW ENZO IS POSITIONED TO CREATE SUSTAINED VALUE FOR ITS SHAREHOLDER S Industry Challenge Enzo Solution  While demand for MDx is rapidly increasing , reimbursement is rapidly declining – and lab margins could decline by an additional 20 - 30 percentage points under new payment pol

  12. Slide 12: MDx Market Growth

    11 MD x MARKET GROWTH ($ in billions)  In the span of 25 years, molecular diagnostics have burgeoned from a practically non - existent market of approximately $10 million in product sales to $ 5.2 billion worldwide in 2014  Estimated annual growth rate of 7.5% at least through 2018  Thousands of

  13. Slide 13: MDx Market Challenges

    12 MD x MARKET CHALLENGES  Demand for MDx is rapidly increasing, and we believe it is growing at 2x the rate of the overall diagnostic market (1)  Despite growing demand, reimbursement for MDx tests is in long - term decline (1)  MDx margins within labs could decline by another 20 - 30 percentage

  14. Slide 14: Market Problem Explained

    Increasing demand for MDx Tests. Aging population and efficacy of tests is expected to see MDx demand continue to grow (see slide 11) 13 MARKET PROBLEM EXPLAINED Clinical Labs Payors (Insurance & MEDICARE) Diagnostic Test Companies Despite increased d emand, payors are reducing reimbursemen t rates

  15. Slide 15: Enzo's Solution for the MDx Market

    14 ENZO’S SOLUTION FOR THE MD x MARKET Clinical Labs or Enzo’s Lab Which should enable the clinical labs to make an acceptable margin on certain high - value, high - growth MDx tests $ Enzo’s products fit open - systems which are currently being underutilized by the clinical labs 3 4 WIN - WIN - WIN

  16. Slide 16: Market Problem: Closed Systems

    15 MARKET PROBLEM : CLOSED SYSTEMS Closed MDx System MDx Test  “Company A” makes the MDx test  “Company A” also makes the MDx closed s ystem that can only use “Company A’s ” MDx t est  Closed - end systems are developed by MDx companies to perform MDx tests that only accept proprietary reagents 

  17. Slide 17: Enzo Solution: Develop Content for Open Systems

    16 ENZO SOLUTION : DEVELOP CONTENT FOR OPEN SYSTEMS  Enzo makes multiple high - quality MDx Assays  Which are lower - priced and can fit into most “open ” MDx systems  Recently (<5 years), inexpensive open systems have become widely available, but high - value content is lacking due to third part

  18. Slide 18: MDx Market Has Material Inefficiencies

    17 MD x MARKET HAS MATERIAL INEFFICIENCIES Intellectual Property Biotech Innovation, Technology, and Test Platforms MDx Develop, Validate, and Manufacture Products Product Distribution, Sales, and Marketing Clinical Services $ $ $ $ Billing Payors Cost Cost Cost Cost Reimbursement Pressures The Mult

  19. Slide 19: Enzo's Vertical Integration Has Material Advantages

    18 ENZO’S VERTICAL INTEGRATION HAS MATERIAL ADVANTAGES Intellectual Property Biotech Innovation, Technology, and Test Platforms MDx Develop, Validate, and Manufacture Products Product Distribution, Sales, and Marketing Clinical Services $ $ $ $ Billing Payors Cost Cost Cost Cost Reimbursement Pressu

  20. Slide 20: Enzo's Solution: Vertical Integration

    Innovation & IP Technology Platform Manufacturing Technology Validation Products Services Biotech Competitors P P O O O O MDx Competitors Via Licenses P P P O Clinical Service Competitors O O O O O P P P P P P P 19 ENZO’S SOLUTION: VERTICAL INTEGRATION BIOTECH, MD x, AND CLINICAL SERVICES COMPANIES

  21. Slide 21: Why Enzo Believes It Can Deliver 30%-50% Savings

    20 WHY ENZO BELIEVES IT CAN DELIVER 30% - 50% SAVINGS TO MARKET Average Gross Margin of Clinical Services Companies (1) ~30% Potential MDx Savings: Cumulative Royalty Relief  Enzo owns all of its IP  Intellectual property generation already paid for Lower Cost of Goods  Enzo’s cumulative technolo

  22. Slide 22: Analyst quote on AmpiProbe approval

    21 “[Y] ou guys are doing a really good job. Getting AmpiProbe approved is a game changer .” Norman Hale, Stifel , 12/8/2015

  23. Slide 23: Two of Enzo's Proprietary Platforms: AmpiProbe and FlowScript

    22 JUST TWO OF ENZO’S PROPRIETARY PLATFORMS AMPIPROBE ™ FLOWSCRIPT ™ Less Sample x Allows paneling/reduced reaction volume/lower prep costs Multiplex Capability x Able to run up to 30 assays simultaneously Zero Background x After more than 60 cycles x Competitors have issues 100% Concordance x Exist

  24. Slide 24: The Market Is Rewarding Enzo's Progress

    23 THE MARKET IS REWARDING ENZO’S PROGRESS 6 - Month Total Shareholder Return Note: Selected Lab Peers: GHDX, NEO, SQNM, SHL, NTRA, and VCYT (Median value used) Note: Selected Life Science Peers: AFFX, NSTG, EXQ, HBIO, and TECH (Median value used) Source: Capital IQ as of November 24, 2015 86.0% -40

  25. Slide 25: Recent Catalysts Are Validating Enzo's Strategy

    0 100 200 300 400 500 600 700 800 900 1000 $2.50 $3.00 $3.50 $4.00 $4.50 $5.00 Volume (Thousands) Stock Price October 29, 2015: Enzo announces it has demonstrated new thresholds of sensitivity and breadth for its assay for the measurement of Hepatitis C virus (HCV) viral load November 17, 2015: Enzo

  26. Slide 26: Recent Results Demonstrate Our Strategy Is Working

    25 ENZO RECENT RESULTS DEMONSTRATE THAT OUR STRATEGY IS WORKING $15,822 $17,090 $15,000 $15,500 $16,000 $16,500 $17,000 $17,500 Q1 2015 Q1 2016 Clinical Laboratory Services Revenue (in thousands) 36.0% 39.5% 34.0% 35.0% 36.0% 37.0% 38.0% 39.0% 40.0% Q1 2015 Q1 2016 Clinical Laboratory Services Gross

  27. Slide 27: Summary

    26 SUMMARY  The Company continually evaluates its own technologies and platforms and selects those to further advance based on the following criteria:  Products that solve problems for clinical labs and have existing market opportunities  Products that can be sold at 30% - 50% less than our compe

  28. Slide 28: The Problems with Lone Star

    December 2015 www.enzo.com The Problems with Lone Star 27

  29. Slide 29: Lone Star: lack of ideas, selling stock during proxy fight

    28 Lone Star:  Complete lack of ideas for Enzo’s Business – thus resorting to disingenuous personal attacks and red herring critiques  Rapidly selling their Enzo stock while waging a proxy fight ( see pages 30 - 31) WHY DOES LONE STAR THINK THIS IS OKAY? DO THEY CARE AT ALL ABOUT THEIR CREDIBILITY

  30. Slide 30: Lone Star Value's Lack of Specificity and Value-Add

    29 LONE STAR VALUE’S LACK OF SPECIFICITY AND VALUE - ADD  An investment manager called Lone Star Value Management LLC (“Lone Star”) with a 1.23% position in Enzo is currently seeking 40% representation on Enzo’s board (1)  We believe Lone Star’s interests are not aligned with other shareholders –

  31. Slide 31: Is Lone Star a Shareholder or a Trader?

    30 IS LONE STAR A SHAREHOLDER OR A TRADER? Common Stock 5,000 10/1/15 Common Stock 10,000 10/19/15 Common Stock (55,000) 10/30/15 Common Stock (5,000) 10/30/15 Common Stock (25,000) 11/2/15 Common Stock (5,000) 11/2/15 Common Stock (31,300) 11/4/15 Common Stock (2,236) 11/4/15 Common Stock (18,897)

  32. Slide 32: Lone Star Owns Less Enzo Stock Than Two Years Ago

    31 LONE STAR OWNS LESS ENZO STOCK THAN IT DID TWO YEARS AGO (1,000,000) (800,000) (600,000) (400,000) (200,000) - 200,000 400,000 600,000 800,000 1,000,000 -400,000 -300,000 -200,000 -100,000 0 100,000 200,000 300,000 400,000 Nov-13 Dec-13 Feb-14 Feb-14 May-14 Feb-15 Apr-15 Sep-15 Nov-15 Last Two Ye

  33. Slide 33: Abysmal Track Record

    32 ABYSMAL TRACK RECORD 125.9% 74.5% 56.2% - 8.1% - 11.5% - 20.0% - 21.8% - 26.9% - 34.2% - 35.3% - 38.9% - 47.06% - 54.1% - 56.8% - 64.1% - 83.1% - 87.0% - 91.1% - 99.8% - 99.9% -100.0% -50.0% 0.0% 50.0% 100.0% 150.0% LONE STAR’S TRACK RECORD, WE BELIEVE, SPEAKS FOR ITSELF Median = Negative 37.1% S

  34. Slide 34: The Choice for Shareholders Is Clear

    x A business model and operational structure that are positioned to address the imminent needs of the growing but challenged MDx industry x The ability to further leverage Enzo’s vertically integrated business structure to create value for shareholders x A board and management team with a deep under

  35. Slide 35: Addressing Lone Star's December 17th Presentation to ISS

    December 2015 www.enzo.com Addressing Lone Star’s December 17 th Presentation to ISS 34

  36. Slide 36: Is Lone Star a Long-Term Enzo Shareholder?

    35 HOW CAN LONE STAR LOOK ISS IN THE EYE AND SAY “WE ARE A LONG - TERM ENZO SHAREHOLDER”? LONE STAR IS ANYTHING BUT A LONG - TERM SHAREHOLDER OF ENZO Source: Lone Star Investor Presentation filed December 17, 2015 (1) Lone Star meeting with Company Lone Star has been aggressively selling Enzo’s stoc

  37. Slide 37: Lone Star Asserts Enzo Lacks Execution

    36 LONE STAR ASSERTS THAT ENZO “LACKS EXECUTION” Developing and monetizing Enzo’s substantial IP portfolio is a direct result of execution of our strategic plan. Is L one Star suggesting their nominees have superior IP litigation experience to Enzo’s world class counsel who works on a contingency ba

  38. Slide 38: Could Lone Star's Lawyer Nominees Assist with IP Litigation?

    37 COULD LONE STAR’S LAWYER NOMINEES “ASSIST” WITH OUR IP LITIGATIO N? http://www.desmaraisllp.com/lawyers/john - m - desmarais  Enzo has retained John Desmarais as its IP litigation counsel – with a 100% contingency arrangement  Desmarais is one of the most successful IP litigators ever http://ww

  39. Slide 39: Does Enzo Need Help from Lone Star's IP Experts?

     Enzo has consistently been at the frontier of innovation, committed to investing in the development of disruptive technologies  Having a wide range of applications, Enzo’s IP estate of patents (of which our CEO is co - inventor) has been regularly infringed upon, enriching a number of major compa

  40. Slide 40: Who Is Lone Star?

    39 WHO IS LONE STAR? The assertion that Lone Star’s nominees are independent is laughable (see pages 61 - 65) Lone Star’s assertion that it has a “long term focus” is not substantiated by the facts (see page 31) Indeed Mr. Eberwein does have “extensive board experience” as he has sat on 11 different

  41. Slide 41: Lone Star's One Page Plan

    40 LONE STAR’S ONE PAGE “PLAN” “EXAMINING” IS NOT A PLAN! Why would shareholders elect Lone Star’s nominees – which would represent 2/3 of the independent directors – so that they can “examine” our business? Have they seen that our operational metrics are rapidly improving? Do they really think we n

  42. Slide 42: Lone Star Nominees Have No Plan

    41 LONE STAR NOMINEES HAVE NO PLAN  Enzo acknowledges that the Company has yet to achieve its full potential  We have been executing on a multi - year strategic plan to dramatically improve performance and create sustained value for shareholders  Our strategy is beginning to bear the fruit of thi

  43. Slide 43: Settlement Offer

    42 “SETTLEMENT OFFER” ENZO REFUSES TO “SETTLE” WITH NOMINEES WHO HAVE ZERO IDEAS AND AN ABYSMAL TRACK RECORD ▪ It would have been remarkably easy for us to have simply expanded the Board and add a Lone Star nominee to avoid the expense and distraction of a contested election ▪ However , we obviously

  44. Slide 44: Related Party Transactions

    43 “RELATED PARTY TRANSACTIONS” THIS SINGLE RELATED PARTY TRANSACTION IS NOT A “NON - ISSUE” IT IS IN FACT AN EXCELLENT ARRANGEMENT FOR ENZO SHAREHOLDERS Lone Star’s attempt to depict the Company’s clinical lab lease as somehow unfair or enriching the management team at the expense of shareholders,

  45. Slide 45: Related Party Transactions

    44 “RELATED PARTY TRANSACTIONS”  In its preliminary proxy statement, Lone Star expresses concerns regarding the Company’s “ related - party transactions”  Although Lone Star repeatedly states "transactions ” to suggest that there are multiple, there is, in fact, a single related - party transactio

  46. Slide 46: Addressing Lone Star's Commentary Regarding Our Board

    45 ADDRESSING LONE STAR’S ERRONEOUS COMMENTARY REGARDING OUR BOARD LONE STAR SHOWS ITS COMPLETE LACK OF INTEGRITY BY ITS SLANDEROU S ATTACKS ON OUR DIRECTORS Mr. Perlysky has run a family office for over 17 years where he has extensive experience investing in biotech and life science companies Sourc

  47. Slide 47: Lone Star Is Dragging Family Members into Its Proxy Fight

    46 LONE STAR IS DRAGGING FAMILY MEMBERS INTO ITS PROXY FIGHT • This slide that Lone Star put forward to ISS is an attempt to tie Mr. Perlysky to certain members of his wife’s family in another effort to characterize Mr. Perlysky as somehow immoral or involved in criminal activity. This is absolutely

  48. Slide 48: Our Board Has an Excellent Track Record

    47 OUR BOARD HAS AN EXCELLENT TRACK RECORD • The original investors joining Mr. Perlysky into the company paid $0.50/share . A later financing was done at $0.72 share. The company now trades at $ 1.00 per share. The company went from $ 147 thousand to $ 22 million in stockholder equity and currently

  49. Slide 49: Director Qualifications

    48 DIRECTOR QUALIFICATIONS Mr. Bortz has made a career out of helping companies maximize their potential and improve operating performance – it is his primary expertise Mr. Bortz been a director of Enzo since 2010 Mr. Perlysky is an engaged investor who regularly works with portfolio companies to im

  50. Slide 50: Lone Star Nominee: Dimitrios Angelis

    49 Enzo does not need another lawyer OTI was not a success under Mr. Angelis (see page 50) Why was Mr. Angelis tenure at Wockhardt and Osteotech so short? LONE STAR NOMINEE: DIMITRIOS ANGELIS Source: Lone Star Investor Presentation filed December 17, 2015 All three of Mr. Angelis’ public boards have

  51. Slide 51: Lone Star Nominee: Dimitrios Angelis

    50 LONE STAR NOMINEE: DIMITRIOS ANGELIS  Mr. Angelis is currently on the boards of Digirad (with Mr. Eberwein and Mr. Climaco) and Ameri100  Mr. Angelis’ most recent full - time position was serving as CEO of On Track Innovations (where Mr. Eberwein, Mr. Gillman, and Mr. Singh were all on the Boar

  52. Slide 52: Lone Star Nominee: John Climaco

    51 LONE STAR NOMINEE: JOHN CLIMACO Is a director at Perma - Fix and then pivoted to become a full - time employee See Infusystems case study (page 73 - 74) Digirad is now a customer of Perma - Fix and Digirad is now a shareholder of Perma - Fix. Does that seem appropriate? Digirad made an unsolicite

  53. Slide 53: Lone Star Nominee: John Climaco

    52 LONE STAR NOMINEE: JOHN CLIMACO If Mr. Climaco was so proud of his accomplishments at Alco, why did he leave these details out of his list of “public board experience” when he presented Enzo’s nominating committee with his resume? (See page 55) Source: Lone Star Investor Presentation filed Decemb

  54. Slide 54: Lone Star Nominee: John Climaco

    53 LONE STAR NOMINEE: JOHN CLIMACO  Enzo’s management team has known Mr. Climaco for approximately three years  We were first introduced to Mr. Climaco when he approached Enzo in an effort to explore channels of distribution for his Axial Biotech product, which we turned down after being entirely

  55. Slide 55: Nominee failed to disclose significant facts

    54 We are concerned that a Lone Star nominee failed to disclose significant facts in his background and only disclosed them upon questioning by our Nominating and Governance Committee

  56. Slide 56: John Climaco Case Study: Alco Stores

    55 JOHN CLIMACO CASE STUDY: ALCO STORES (100%) -120.0% -100.0% -80.0% -60.0% -40.0% -20.0% 0.0% February 18, 2014: Concerned ALCO Stockholders (“CAS”) announced its intent to nominate board candidates in ALCO’s 2014 election August 29, 2014: ALCO announced the completion of its annual meeting where

  57. Slide 57: Lone Star's Conclusion

    56 LONE STAR’S “CONCLUSION” Enzo’s stock is up more than 70% in the last three years and 55% in the last three months WHAT PLAN? Source: Lone Star Investor Presentation filed December 17, 2015 HOW CAN LONE STAR ASSERT THEY HAVE A “BETTER PLAN” WHEN THEY DON’T HAVE ANY PLAN

  58. Slide 58: Additional Background on Lone Star

    December 2015 www.enzo.com Additional Background on Lone Star 57

  59. Slide 59: Eberwein's activist track record

    58  We believe that Mr. Eberwein’s track record as an activist investor and corporate director appears to be quite poor  S ince starting his activist fund in 2012, Mr. Eberwein has been one of the most activist investors in the U.S., routinely targeting smaller - cap companies in diverse industrie

  60. Slide 60: Lone Star Value Scorecard

    Lone Star’s Investments that Have Seen Increased Shareholder Value 59 LONE STAR VALUE SCORECARD Companies whose Shareholder Value Decreased when Lone Star Gained Board Representation 15 3 Source: FactSet

  61. Slide 61: Lone Star's Nominees Are Not Independent

    60 LONE STAR’S NOMINEES ARE NOT INDEPENDENT  When Mr. Eberwein first suggested Mr. Angelis and Mr. Climaco for the Board of Enzo, he asserted that they were “completely independent” and that he had met them on the Board of Digirad (1)  A closer examination, however, shows in no uncertain terms tha

  62. Slide 62: Independent Directors?

    61 INDEPENDENT DIRECTORS? Jeff Eberwein Dimitrios Angelis John Climaco Chuck Gillman Dilip Singh Supporter Largest Shareholder Largest Shareholder Richard Coleman Jr. Boston Avenue Capital, LLC Proponent Source: FactSet BANKRUPT (Climaco is EVP of parent company)

  63. Slide 63: Director Relationships

    62 DIRECTOR RELATIONSHIPS WE BELIEVE THAT LONE STAR OBTAINING A DIRECTOR SEAT ON ENZO’S BO ARD IS A BENEFIT SOLELY TO LONE STAR, BUT NOT NECESSARILY A BENEFIT TO AL L THE ENZO SHAREHOLDERS Total Public Boards Boards with Eberwein Boards with Climaco Boards with Angelis Jeffrey Eberwein 11 2 3 John C

  64. Slide 64: Lack of Independence: Digirad's Failed Bid for PDI

    63 LACK OF INDEPENDENCE: DIGIRAD’S FAILED BID FOR PDI  In October 2013, John Climaco joined the Board of PDI, Inc.  On October 29, 2014, John Climaco resigned from PDI’s Board of Directors  On October 29, 2014, the same day as Climaco’s resignation , Digirad, where Mr. Eberwein is a director, sen

  65. Slide 65: What's Going On at Digirad?

    64 WHAT’S GOING ON AT DIGIRAD ? On July 24, 2015, the Company’s majority - owned Polish subsidiary, Perma - Fix Medical and Digirad Corporation, a Delaware corporation (“ Digirad ”), Nasdaq: DRAD, entered into a multi - year Tc - 99m Supplier Agreement (the “Supplier Agreement”) and a Series F Stock

  66. Slide 66: Digirad and Perma-Fix

    65 DIGIRAD AND PERMAFIX NOW PERMAFIX HAS A SLIDE ON DIGIRAD IN ITS INVESTOR PRESENTATION, WHY? Source: Perma - Fix Medical Investor Presentation, June 2015

  67. Slide 67: Jeffrey Eberwein Case Study: Aetrium

    66 JEFFREY EBERWEIN CASE STUDY: AETRIUM -80.0% -60.0% -40.0% -20.0% 0.0% 20.0% 40.0% 60.0% 80.0% August 14, 2012: Jeffrey Eberwein and Archer Advisors LLC filed a joint Schedule 13D (Concerned Aetrium Shareholders (“CAS”)) reporting a 16.7 % stake in the Company November 29, 2012: CAS filed a lawsui

  68. Slide 68: Lone Star Case Study: Antares

    67 LONE STAR CASE STUDY: ANTARES “The Board of Directors believe Lone Star Value Management brought nothing of merit to Antares and the lack of veracity of their statements was clearly demonstrated by the failure of Jeffrey Eberwein to attend the General Meeting he imposed upon Shareholders at which

  69. Slide 69: Lone Star Case Study: Aviat

    68 LONE STAR CASE STUDY: AVIAT -50.00% -40.00% -30.00% -20.00% -10.00% 0.00% 10.00% 20.00% October 6, 2014: Lone Star issues a press release and disclosed its intent to nominate six candidates for election to Aviat’s board at the 2014 annual meeting January 12, 2015: Aviat announced the reaching of

  70. Slide 70: Lone Star Case Study: CIBER

    69 LONE STAR CASE STUDY: CIBER -45.0% -40.0% -35.0% -30.0% -25.0% -20.0% -15.0% -10.0% -5.0% 0.0% 5.0% 10.0% February 27, 2014: Lone Star submitted formal notice to nominate three candidates to CIBER’s Board at the 2015 annual meeting April 20, 2014: CIBER announced the nomination of a new independe

  71. Slide 71: Lone Star Case Study: Dakota Plains Holdings

    -90.00% -80.00% -70.00% -60.00% -50.00% -40.00% -30.00% -20.00% -10.00% 0.00% 10.00% 70 LONE STAR CASE STUDY: DAKOTA PLAINS HOLDINGS December 15, 2014: Lone Star, a 7.3% holder, urged the company’s B oard to use a Master Limited Partnership for the Pioneer transloading business and to initiate a rev

  72. Slide 72: Lone Star Case Study: Endeavour International

    -80.0% -60.0% -40.0% -20.0% 0.0% 20.0% 40.0% 60.0% 71 LONE STAR CASE STUDY: ENDEAVOUR INTERNATIONAL July 23, 2013: Endeavour Investors for Shareholder Value (EISV) (Including Jeff Eberwein) filed a joint 13D reporting a combined 16.7% stake. EISV urged the company to evaluate strategic alternatives.

  73. Slide 73: John Climaco Case Study: Essex Rental Corp.

    - 64.1% -80.0% -60.0% -40.0% -20.0% 0.0% 20.0% 40.0% 60.0% 80.0% 100.0% 72 JOHN CLIMACO CASE STUDY: ESSEX RENTAL CORP. February 26, 2015: Casey Capital LLC filed Schedule 13D June 5, 2015: Essex announced the Board’s decision to accept the nomination of John Keddie and John Climaco to the board Sour

  74. Slide 74: InfuSystem Case Study

    73 INFUSYSTEM CASE STUDY A COMPANY FOUNDED BY CHUCK GILLMAN AND SUPPORTED BY JEFFREY EBER WEIN ENTERED A SETTLEMENT WITH INFUSYSTEM TO PLACE CHUCK GILLMAN, JOHN CLIMACO, AND DILIP SINGH ON THE BOARD  On January 18, 2012, Meson Capital Partners, Kleinheinz Capital Partners, and Boston Avenue Capital

  75. Slide 75: InfuSystem Case Study (Cont.)

    - 11.52% -30.00% -25.00% -20.00% -15.00% -10.00% -5.00% 0.00% 5.00% 10.00% 15.00% 20.00% 74 INFUSYSTEM CASE STUDY (CONT.) 68.64% -40.00% -20.00% 0.00% 20.00% 40.00% 60.00% 80.00% 100.00% 120.00% 140.00% 160.00% 180.00% Stock Performance with Climaco on Board Stock Performance after Climaco Left the

  76. Slide 76: Lone Star Case Study: Hudson Global

    75 LONE STAR CASE STUDY: HUDSON GLOBAL -50.0% -40.0% -30.0% -20.0% -10.0% 0.0% 10.0% 20.0% January 21, 2014: Lone Star Value Management, Bradley Radoff, and Richard Coleman filed a joint Schedule 13D, reporting a combined stake of 6.8% December 2, 2013: Heartland Advisors, Charles Gillman, and other

  77. Slide 77: Eberwein Case Study: MAG Silver

    76 EBERWEIN CASE STUDY: MAG SILVER -60.0% -50.0% -40.0% -30.0% -20.0% -10.0% 0.0% 10.0% 20.0% 30.0% 40.0% April 3, 2012: Mason Hill Advisors filed a Schedule 13D, reporting an 8.5% stake in the Company and that it had engaged in strategic alternatives discussions with the company June 29, 2012: Jeff

  78. Slide 78: Lone Star Case Study: Miller Energy

    -120.0% -100.0% -80.0% -60.0% -40.0% -20.0% 0.0% 77 LONE STAR CASE STUDY: MILLER ENERGY December 17, 2013: Concerned Miller Shareholders (CMS), led by Bristol Capital Advisors and Lone Star, 4.7% holders, disclosed the nomination of 10 board members at Miller’s 2014 annual meeting March 31, 2014: Th

  79. Slide 79: Lone Star Case Study: Novation

    78 LONE STAR CASE STUDY: NOVATION -60.00% -40.00% -20.00% 0.00% 20.00% 40.00% 60.00% 80.00% April 22. 2015: Novation Companies announced in a press release a settlement agreement with Lone Star. Per the agreement, the company would appoint Jeffrey Eberwein and Robert G. Pearse to the Board. The comp

  80. Slide 80: Lone Star Case Study: O2Micro

    79 LONE STAR CASE STUDY: O2MICRO -30.0% -20.0% -10.0% 0.0% 10.0% 20.0% 30.0% 40.0% November 25, 2014: Lone Star filed a Schedule 13D, reporting a stake of 5.6% in O2Micro. It proposed that the company streamline operations, repurchase shares/issue a dividend, liquidate long - term equity investments

  81. Slide 81: Lone Star Case Study: Penn Virginia Corporation

    80 LONE STAR CASE STUDY: PENN VIRGINIA CORPORATION -100.0% -90.0% -80.0% -70.0% -60.0% -50.0% -40.0% -30.0% -20.0% -10.0% 0.0% June 26, 2015: Lone Star, a 2.8% holder owning 1.975 million shares of Penn Virginia stock, issued a press release suggesting the company assesses strategic alternatives Sep

  82. Slide 82: Lone Star Case Study: Rentech

    81 LONE STAR CASE STUDY: RENTECH -100.0% -80.0% -60.0% -40.0% -20.0% 0.0% 20.0% 40.0% January 13, 2014: The Concerned Rentech Shareholders Group (Engaged Capital and Lone Star Value Management) (CRS) announced the nomination of four directors to the Board of Rentech March 20, 2014: CRS filed a preli

  83. Slide 83: Lone Star Case Study: SWS Group

    82 LONE STAR CASE STUDY: SWS GROUP -15.00% -10.00% -5.00% 0.00% 5.00% 10.00% January 13, 2014: Lone Star, a 2.3% holder, issued a press release urging the company to put itself up for sale after the Hilltop Holdings offer of $7 per share August 8, 2014: Lone Star reported a 5.5% stake in the company

  84. Slide 84: The Choice for Shareholders Is Clear

    x A business model and operational structure that are positioned to address the imminent needs of the growing but challenged MDx industry x The ability to further leverage Enzo’s vertically integrated business structure to create value for shareholders x A board and management team with a deep under

  85. Slide 85: Enzo's Leadership

    December 2015 www.enzo.com Enzo’s Leadership 84

  86. Slide 86: Elazar Rabbani and Barry Weiner

    85 ELAZAR RABBANI, Ph . D . , is an Enzo Biochem founder and has served as the Company’s Chairman of the Board and Chief Executive Officer since its inception in 1976 and Secretary since November 25 , 2009 . Dr . Rabbani has authored numerous scientific publications in the field of molecular biology

  87. Slide 87: Dieter Schapfel, M.D.

    86 DIETER SCHAPFEL, M . D . , Chief Medical Director for Enzo Clinical Labs, has been employed with the Company since 2012 , initially as a consulting pathologist . Dr . Schapfel served as Medical Director of Pathology at Southside Hospital – North Shore/Long Island Jewish Health System from 2006 to

  88. Slide 88: Independent Director Bortz

    87 Mr . Bortz is an Independent Director of Enzo Biochem, Inc. He co - founded CREO and leads its investment management business. With over 19 years of experience in developing and managing investments for high - net - worth individuals, families, and institutions, Mr. Bortz has generated sizeable r

  89. Slide 89: Dov Perlysky

    88 DOV PERLYSKY Mr . Perlysky is an Independent Director of Enzo Biochem , Inc .. He is also an Independent Director at Highlands Bancorp, Inc . , Independent Director at Pharma - Bio Serv , Inc . , and Managing Member at Nesher LLC . He is on the Board of Directors at Enzo Biochem , Inc .; Oak Tree

  90. Slide 90: Bernard L. Kasten, M.D.

    89 BERNARD L. KASTEN, M.D Dr Kasten has been a Director of Enzo BioChem Inc . since January 2008 . He presently is Enzo’s Lead Independent Director . He was Chairman of the Board of Cleveland Biolabs , Inc . (CBLI : NASDAQ) August 2006 to 2014 . From 1996 to 2004 , Dr . Kasten served at Quest Diagno

  91. Slide 91: Contact Information

    90 CONTACT INFORMATION Bruce H. Goldfarb/Patrick J. McHugh/Michael Fein (212) 297 - 0720 / (877 ) 629 - 6356 info@okapipartners.com Shareholders

Enzo Biochem — Proxy Contest (December 2015) on 6ix